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cense.Abstract Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
which can cause prominent central nervous system (CNS) involvement. Cognitive dysfunction is
one of the major neuropsychiatric syndromes of SLE.
Aim of the work: To evaluate cognitive functions in SLE patients without evident neuropsychi-
atric manifestations and to ﬁnd out if it is correlated with disease activity and with treatment.
Patients & methods: Thirty SLE patients without evident neuropsychiatric manifestations were
evaluated. The evaluation included full clinical examination, assessment of SLE disease activity
index-2k (SLEDAI-2k), routine laboratory investigations, autoantibodies assessment and cognitive
function assessment using Montre´al cognitive assessment (MoCA) scale and trail making test
(TMT) (part A and part B). Twenty apparently healthy individuals were taken as control.
Results: Cognitive dysfunction is present in all SLE patients included in our study. During
assessment of cognitive functions, a highly statistically signiﬁcant difference was observed between
patients and control subjects, even with equal levels of education. While patients with higher1144704146.
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68 A.M. El-Shafey et al.educational levels were as impaired as those with lower levels of education. Cognitive dysfunction
was not correlated with disease activity or with the doses of drugs used for treatment. But a statis-
tically signiﬁcant positive correlation was noted between deterioration of cognitive functions and
the disease duration.
Conclusion: Cognitive dysfunction is a prominent feature in SLE patients without symptoms of
CNS involvement. Psychological evaluation should be performed for each SLE patient to detect
cognitive dysfunctions. Psychological intervention is recommended to prevent further deterioration.
Correlation with disease duration should pay attention to the chronicity of disease.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease that is characterized by multisystem involvement and
diverse manifestations. It can affect almost any organ in the
body; the primary areas affected by SLE include the heart,
lungs, skin, joints, blood-forming organs, kidneys, and the cen-
tral nervous system (CNS) [1].
Over 50% of patients with SLE demonstrate major psychi-
atric and neurologic disorders indicating CNS involvement.
Neuropsychiatric (NP) syndromes in SLE may include major
manifestations, such as stroke syndromes, seizures, and psy-
chotic episodes. They may also include less severe abnormali-
ties including headaches, minor mood disorders, and
cognitive difﬁculties [2].
In the revised criteria for neuropsychiatric lupus, 19 neuro-
psychiatric syndromes were deﬁned including 11 CNS disor-
ders and eight peripheral nervous system disorders. In this
revised nomenclature, cognitive dysfunction was identiﬁed as
one of the major neuropsychiatric syndromes and was deﬁned
as ‘‘signiﬁcant deﬁcits in any or all of the following cognitive
functions: complex attention, executive skills (e.g., planning,
organizing, sequencing), memory (e.g., learning, recall), vi-
sual-spatial processing, language (e.g., verbal ﬂuency), and
psychomotor speed’’ [3].
Studies to date suggest that cognitive impairment in SLE is
in part mediated by autoantibody activity and mechanisms
associated with ischemia [4]. Additional mediators of cognitive
function in SLE patients include health characteristics (disease
activity, disease duration, medication use), immune activity
(autoantibodies, proinﬂammatory cytokines), and behavioral
factors such as depression, pain, and fatigue [5].
It has been claimed that a subset of anti-DNA antibodies
cross reacts with a sequence in the extracellular ligand-binding
domain of NR2 receptors [6]. These receptors are subtypes of
N-methyl-D-aspartate (NMDA) receptors which bind to the
excitatory neurotransmitter glutamate. They are present at
high density in the hippocampus, which is closely linked to
learning and memory [7].
Omdal et al. reported an association between anti-NR2
antibodies and decreased short-term memory and learning
[8], and also with depressed mood [9].
Antiphospholipid syndrome is associated with focal mani-
festations of NPSLE, such as stroke and seizures [10]. Persis-
tently elevated levels of anti-cardiolipin antibodies (ACL) are
associated with decline in cognitive dysfunction, possibly due
to thrombosis within vessels of minute calibers [11].
A previous study identiﬁed a relationship between serum IL-
6 production and learning deﬁcits in SLE. It was alsodemonstrated that elevated levels of C-reactive protein
(CRP) are correlated with deﬁcits in information processing
[12].
Patients with neuropsychiatric systemic lupus erythemato-
sus (NPSLE), especially those with cognitive impairment were
found to have elevated levels of matrix metalloproteinase-9
(MMP-9) in the serum [13] and in the cerebrospinal ﬂuid
(CSF) [14].
The aim of this study was to evaluate the state of cognitive
functions in SLE patients without evident neuropsychiatric
manifestations and to ﬁnd out if it correlated with disease
activity and with treatment or not.2. Patients and methods
2.1. Patients
Fifty subjects were included in this study. All subjects were re-
cruited from the out-patient clinics and follow-up units of the
Rheumatology and Rehabilitation Departments, Faculty of
Medicine, Zagazig University Hospitals. They were divided
into two groups. The ﬁrst group (I): included 30 SLE patients
suffering from lupus nephritis and treated by corticoste-
roids with either pulsed cyclophosphamide therapy or oral
azathioprine. They were diagnosed according to the revised
American College of Rheumatology (ACR) criteria for classi-
ﬁcation of SLE [15]. The second group (II): included 20
apparently healthy subjects, matched for age, sex, total years
of education, and social backgrounds, taken as a control
group.
In this study, we excluded patients with major psychiatric
disorders, mental retardation or family history of organic men-
tal disorders. SLE patients with known comorbid neurologic
conditions (traumatic brain injury; degenerative, vascular, or
metabolic disorder; neoplasm, or toxic exposure), major sub-
stance abuse, or major psychopathology were excluded from
the study. An informed consent was taken from all subjects re-
cruited for the study.
2.2. Clinical and laboratory evaluation
All subjects of our study were subjected to full history taking,
thorough physical examination and laboratory investigations
such as: complete blood count (CBC), erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), complete urine
analysis, 24-h urinary proteins, C3 level, antinuclear antibody
(ANA) by immunoﬂuorescent assay, anti-double stranded
DNA (Anti-Ds. DNA) done by latex agglutination test and
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assay (ELISA). Assessment of disease activity was done by
using systemic lupus erythematosus disease activity index-2k
(SLEDAI-2k) [16].
2.3. Assessment of cognitive functions
Assessment of cognitive functions was done by:
a. Montre´al cognitive assessment (MoCA) scale [17].
MoCA scale includes several aspects of cognitive
functions. Actually, it is divided into several subcores
including visuospatial and executive functions, naming,
attention, language, abstraction, delayed recall, and ori-
entation [18].
b. Trail making test (TMT) (part A and part B): The TMT
assesses mental shifting and consists of two parts. First,
the subject is required to draw lines to connect numbers
in ascending order as quickly as possible. This part
(TMT A) assesses visual perception rapidity and psycho-
motor rapidity. The second part (TMT B) assesses men-
tal shifting and the subject’s attention ability since s/he is
required to do the same as for TMT A, but alternating
between numbers and letters. The subject is asked to per-
form the task as quickly as possible without lifting his/
her pen. If the experimenter sees a mistake, s/he tells
the patient. The time in seconds required for the perfor-
mance of part A and part B was used for the analysis. If
the time to complete TMTB is longer than 240 s, then the
test is stopped and the number of ﬁgures connected
in the allotted time as well as the number of errors is
noted [19].
Statistical analysis: The data of the patients were entered on
Statistical Package for Social Science (SPSS) [20]. Results are
presented as mean and standard deviation. The non-paramet-
ric un-paired t-test, Mann Whitney U test, is used to assess
differences of cognitive functions between each group. Spear-
man’s correlation coefﬁcient analyses were performed to iden-
tify factors associated with cognitive deﬁcits, such as: MoCA,
TMT A, TMT B, total SLEDAI-2k and renal index. The
statistically signiﬁcant cutoff value was set at p< 0.05.Table 1 Epidemiological and clinical variables of the two studied g
Group I (patients)
Mean ± SD Range
Age (years) 34.56 ± 6.01 25–46
Years of Education 8.27 ± 4.51 1–16
Diseases duration (years) 5.4 ± 2.21 (1.2–6.4
ESR (mm/h) 31.3 ± 12.4 4–55
CRP (mg/dl) 4.86 ± 2.21 3–12
C3 (mg/ml) 65.13 ± 21.07 35–140
ANA (EU/ml) 31.46 ± 6.004 15–45
Anti-DNA (IU/ml) 26.57 ± 6.37 14–42
Anti-cardiolipin (MPL/ml) 5.15 ± 1.51 2.47–7
MoCA 14.66 ± 4.05 11–26
TMT A (s) 38.3 ± 10.53 28–71
TMT B (s) 294.1 ± 10.21 275–31
*Signiﬁcant at P< 0.05 and **Highly signiﬁcant at P< 0.001.3. Results
3.1. Grouping of subjects included in the study
This study was performed on 50 individuals, divided into two
groups:
Group I: It included 30 SLE patients. Twenty-one patients
were suffering from active lupus nephritis, and are under
pulsed cyclophosphamide therapy combined with steroid
treatment, and have completed the ﬁrst 6 monthly doses of
treatment course. The remaining nine patients are under Aza-
thioprine and steroid treatment.
Group II: It included 20 healthy subjects (control group), of
nearly the same epidemiological characters.
All patients and control subjects were further classiﬁed,
according to the number of years of education, into two sub-
groups a and b, less than 12 years and more than 12 years,
respectively.3.2. Comparison between clinical & laboratory variables of the
two groups
The statistical analyses did not show signiﬁcant differences
among SLE patients and control subjects as regards age, years
of education, CRP levels, ACL levels and TMT A scores, while
there were highly statistically signiﬁcant differences between
both groups as regards ESR, C3 levels, ANA and anti-DNA
titers. There were highly statistically signiﬁcant differences be-
tween patients and control subjects as regards TMT B and
MoCA scales for cognitive assessment (Table 1).3.3. Effect of SLE on cognitive function
In subjects with less than 12 years of education, there was a
highly statistically signiﬁcant difference in MoCA, TMT A
and TMT B scores between subgroups I-a and II-a. While in
subjects with more than 12 years of education there was a sta-
tistically signiﬁcant difference in MoCA scores and a highly
statistically signiﬁcant difference in TMT B scores between
subgroups I-b and II-b (Table 2).roups.
II (control) P
Mean ± SD Range
33.4 ± 5.71 25–44 0.495
9.2 ± 4.49 2–16 0.476
) – –
5.45 ± 1.76 3–9 <0.001
4.75 ± 1.48 3–8 0.123
145.1 ± 21.28 110–170 <0.001
14.6 ± 3.09 10–20 <0.001
14.05 ± 2.89 10–19 <0.001
4.69 ± 1.68 2.13–6.8 0.108
27.95 ± 1.19 26–30 <0.001
29.75 ± 1.033 28–32 0.088
2 67.6 ± 4.22 60–74 <0.001
Table 2 Difference in cognition assessment scales between patients and control subjects with the same level of education.
Group mean ± SD <12 years education >12 years education
I-a (patients) N= 22 II-a (control) N= 12 P I-b (patients) N= 8 II-b (control) N= 8 P
MoCA 14.29 ± 3.14** 28.2 ± 1.16 <0.001 17.0 ± 5.50 26.43 ± 3.10* 0.015
TMT A 39.6 ± 11.9** 29.69 ± 1.48 0.008 36.44 ± 6.71 30.17 ± 1.17 0.43
TMT B 293.3 ± 10.70 66.62 ± 4.46** <0.001 294.4 ± 8.03** 69.43 ± 3.36 <0.001
* Signiﬁcant at P< 0.05.
** Signiﬁcant at P< 0.001.
Table 3 Comparison between the two subgroups of patients
as regards cognition assessment scales.
Group I-a (patients
< 12 years education)
I-b (patients
> 12 years education)
P
MoCA 14.29 ± 3.14c 17.33 ± 5.24b 0.017
TMT A 39.6 ± 11.9b 36.44 ± 6.71ab 0.396
TMT B 294.19 ± 11.20b 294.4 ± 8.03b 0.95
*Signiﬁcant at P< 0.05.
**Signiﬁcant at P< 0.001.
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When comparing the two subgroups of patients (> and
<12 years of education) there was a statistically signiﬁcant
difference in MoCA scores, at the same time there is no statis-
tically signiﬁcant difference between two subgroups as regards
TMT A or B (Table 3).
3.5. Relation between disease parameters and cognitive function
There was a statistically signiﬁcant positive correlation be-
tween disease duration and TMT B scores (p= 0.049). WhileTable 4 Correlation between cognitive assessment scales and
disease duration, SLEDAI-2k and renal activity index in group
I.
MoCA TMT A TMT B
r P r P r P
Duration 0.164 0.388 0.218 0.251 0.492* 0.049
SLEDAI-2k 0.148 0.439 0.120 0.532 0.313 0.09
Renal index 0.153 0.422 0.227 0.230 0.049 0.799
*Signiﬁcant at P< 0.05.
** Signiﬁcant at P< 0.001.
Table 5 Correlation of doses of different lines of treatment with d
Group Cyclophosphamide N= 21
r P
MoCA 0.03 0.89
TMT A 0.149 0.513
TMT B 0.257 0.251
SLEDAI-2k 0.731** <0.001
Renal index 0.448* 0.035
* Signiﬁcant at P< 0.05.
** Signiﬁcant at P< 0.001.there was a non-signiﬁcant correlation between disease dura-
tion and TMT A or MoCA scores. There was, also, a non-sig-
niﬁcant correlation between any of cognitive assessment scores
and SLEDAI-2k or renal activity index (Table 4).
3.6. Effect of treatment on cognitive function
There was a highly statistically signiﬁcant negative correlation
between SLEDAI-2k and cyclophosphamide dose. While there
was a statistically signiﬁcant negative correlation between
SLEDAI-2k and steroid dose and between renal activity index
and both cyclophosphamide and steroid dose. None of the
cognitive assessment scores was correlated with the doses of
any of the drugs used in treatment (Table 5).
4. Discussion
SLE is an autoimmune disease with predominance among wo-
men of the child-bearing age. It is characterized by chronic tis-
sue/organ inﬂammation mediated through autoantibodies,
immune complexes, and complement activation that results
in multiorgan involvement [21].
Neuropsychiatric SLE (NPSLE) occurs in 14% to over
80% of patients with SLE and is associated with increased
morbidity and mortality [4].
Cognition is the sum of intellectual functions that result
in thought. It includes reception of external stimuli, informa-
tion processing, learning, storage, and expression [22].
Cognitive dysfunction has been identiﬁed in 14–54% of
non-NPSLE patients suggesting the presence of a subtle
CNS disorder, but investigations into biologic mechanisms
have yet to clearly demonstrate the mechanisms underlying
the phenomenon. Thus, continued studies into the pathogen-
esis of subtle brain involvement in non-NPSLE patients are
warranted [23].
In this study we evaluated 30 SLE patients suffering from
lupus nephritis and evaluated them for the presence ofisease activity and cognitive assessment scores.
Azathioprine N= 9 Steroids N= 30
r P r P
0.172 0.698 0.261 0.163
0.573 0.145 0.155 0.415
0.175 0.691 0.026 0.891
0.072 0.871 0.413* 0.022
0.451 0.277 0.438* 0.015
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and part B), and compared them with 20 healthy control sub-
jects. We found that all our patients were suffering from differ-
ent aspects of cognitive impairment in comparison with the
control group. When performing MoCA scale, only one of
our patients scored as normal and the other 29 patients showed
impairment. While in TMT B, all of the patients showed
impairment in the form of exceeding 240 s to perform the test.
In fact, none of them was able to complete the test even in
longer periods. On the contrary, all patients were able to per-
form TMT A within the normal time as control subjects.
There was a highly statistically signiﬁcant difference be-
tween patients and controls in MoCA scores and TMT B,
while there was no signiﬁcant difference as regards TMT A.
TMT A assesses visual perception rapidity and psycho-
motor rapidity, while TMT B assesses, in addition, mental
shifting and the subject’s attention ability since s/he is re-
quired to alternate between numbers and letters [19]. So,
TMT A is much easier than TMT B. Besides, MoCA scale
measures several aspects of cognitive functions. This is why
our patients showed no signiﬁcant difference with control
subjects as regards TMT A, and showed a highly statistically
signiﬁcant difference with control subjects as regards TMT B
and MoCA scores.
Glanz et al. stated that cognitive dysfunctions occur in 50%
of their SLE patients [24] and Petri et al. reported measurable
cognitive impairment in 75% of SLE patients, using the Auto-
mated Neurophysiological Assessment Metrics (ANAM).
Their patients scored signiﬁcantly lower than controls in the
ANAM [25]. Another study revealed that cognitive dysfunc-
tions occur frequently in SLE patients [26]. Furthermore,
Hanly et al. have conﬁrmed that SLE patients have slower
performance on cognitive tasks than that of controls [22].
In another study, SLE patients had signiﬁcantly lower lev-
els than control subjects in the Mini-Mental State score
(MMSE). They showed, also, signiﬁcantly lower level than
control subjects in Clock Drawing Test (CDT) [27]. In addi-
tion, Ezzat et al. found statistically signiﬁcant differences be-
tween SLE patients and controls in many subsets of
Wechsler Adult Intelligence Scale (WAIS) [28].
By observing these results, we conclude that cognitive dys-
functions are apparent in SLE patients despite using different
methods of assessment.
It was conﬁrmed that SLE patients with CNS involvement
had a higher degree of cognitive impairment than SLE patients
without CNS involvement in the areas of attention/calculation,
auditory comprehension, visuospatial ability, and executive
function [27].
In our study, the three tests were not correlated with total
SLEDAI-2k or with the renal activity index. Neither MoCA
scale nor TMT A was correlated with disease duration.
Whereas TMT B scores had a statistically signiﬁcant positive
correlation with the disease duration.
Trail-Making Test is considered the most difﬁcult and con-
fusing test in our study. Its correlation with disease duration
should pay attention to the occurrence of changes in the brain
tissue of SLE patients.
In another study performed by Bhasin et al., the presence of
cognitive dysfunction in SLE patients did not signiﬁcantly cor-
relate with duration of disease [29].This difference can be ex-
plained by the longer disease duration in our patients which
ranged from 2 to 9 years, while it was 1 to 2 years in that study.The same study had similar results to ours that cognitive
dysfunction in SLE patients did not signiﬁcantly correlate with
indices of disease activity. On the contrary, the Egyptian study
by Ezzat et al. revealed statistically signiﬁcant correlations be-
tween some items of WAIS scale and SLEDAI [28]. At the
same time, Maneeton et al. found that cognitive scores were
not correlated with disease duration or with disease activity
[27].
As regards the treatment received by the patients, none of the
three tests was correlated with the dose of Cyclophosphamide,
Azathioprine or steroid doses. This is in agreement with the re-
sults of Maneeton et al. study, in which the cognitive scores did
not correlate with glucocorticoids, Chloroquine, Methotrexate
or Cyclophosphamide medications [27]. At the same time we
found that total SLEDAI-2k and renal activity index had a
highly signiﬁcant negative correlation with the dose of Cyclo-
phosphamide and a signiﬁcant negative correlation with the
dose of steroids.
In an older study done by McLaurin et al., regular predni-
sone use was associated with decreased cognitive functioning
in middle-aged patients with SLE [30]. While, Bhasin et al.
revealed that the presence of cognitive dysfunction in SLE
patients did not signiﬁcantly correlate with glucocorticoids,
but they found a signiﬁcant correlation of cognitive dysfunc-
tion with use of azathioprine [29].
We conclude that cognitive dysfunctions in SLE occur by
another mechanism rather than that of nephritis. This is why
it is correlated neither with total SLEDAI-2k or with the renal
activity index nor with doses of any of the medications used for
treatment of nephritis.
When we compared patients and control subjects who re-
ceived less than 12 years of formal education, we found a
highly statistically signiﬁcant difference as regards MoCA
and TMT B, and a statistically signiﬁcant difference as regards
TMT A. The difference was, also, highly statistically signiﬁ-
cant between patients & control subjects with more than
12 years of formal education as regards MoCA and TMT B.
When we compared the two subgroups of patients only (i.e.
patients with different levels of education), we found that there
was a statistically signiﬁcant difference between them in the
MoCA score, while the difference was insigniﬁcant as regards
TMT A and B. Those results can be explained by the fact that
MoCA scale measures different domains of cognitive func-
tions. We noted that the visuospatial & executive domains
were the most difﬁcult ones. This is why they can be affected
by the level of education. A non-educated person cannot sim-
ply draw a cube with accurate measures and cannot draw a
clock with accurate numbers and arms on deﬁnite time.
Tomietto et al. observed an independent effect of age on the
development of cognitive impairment and a protective effect of
a high education level on the number of functions impaired
may be due to a greater functional brain reserve that delays
the onset of clinical manifestations [31]. In addition, Brey
et al. identiﬁed an association of age and education with some
measures of cognitive impairment [32]. Tomietto et al. also sta-
ted that the presence of chronic damage (long disease dura-
tion) arose as the main factor affecting the severity of
impairment [31]. In another previous study done by McLaurin
et al., consistent prednisone use and less education were signif-
icantly associated with declining cognitive function especially
in the middle age group and could not be totally explained
by SLE-associated disease activity [30].
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cognitive functions of patients and control subjects as
regards their level of education. But our results in this point
conﬁrm that there is a signiﬁcant impairment in cognitive func-
tions in SLE patients, despite different levels of formal
education.
Study limitations included that patients with low level of
education were not able to perform some parts of cognitive
assessment tests; besides, lack of compliance of the patients
to attend regular psychiatric visits in order to assess the dete-
rioration of the condition.
In conclusion, cognitive dysfunction is a prominent feature
in SLE patients without symptoms of CNS involvement. Psy-
chological evaluation should be performed for each patient to
detect these cognitive dysfunctions. Besides, psychological
intervention is recommended to prevent further deterioration.
Also, correlation with disease duration should pay attention to
the chronicity of disease. Further studies are needed to com-
pare patients with short & long disease duration.Conﬂict of interest
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